Thyroid Cancer Clinical Trial
Verified date | January 2015 |
Source | Yonsei University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Interventional |
Studies have attempted to control pain and increase patients' recovery satisfaction
following many kinds of operations by using as small an opioid analgesic dose as possible
and adding a nonopioid analgesic to reduce the side effects of narcotic analgesics. Among
nonopioid analgesics, lidocaine and magnesium are drawing attention, having been shown to be
helpful in controlling postoperative pain by lowering pain hypersensitivity to surgical
stimuli. Lidocaine acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor. An
intraoperative intravenous injection of lidocaine has been reported to improve postoperative
pain control by reducing postoperative pain and opioid consumption. Another report showed
that an intraoperative intravenous injection of lidocaine improved the quality of
postoperative functional recovery after general anesthesia in a laparoscopic cholecystectomy
patient. In addition, a review article on the effect of intraoperative intravenous injection
of magnesium found it to be an effective analgesic that may be added to conventional
opioid-based therapy because it generally reduces opioid consumption, decreases pain
assessment for 24 hours after surgery, and lacks severe side effects in relation to
magnesium administration. However, there has been insufficient research comparing the
intraoperative intravenous injection of lidocaine or magnesium in terms of which is more
helpful for general functional recovery and decreased postoperative pain. Recently, the
scope of research on anesthesia has come to embrace postanesthetic recovery; to help
patients return to daily life, the research trend is now shifting from the improvement or
resolution of a specific symptom to the measurement of general recovery. Postoperative
recovery is a complicated process related to such catamnestic factors as physiological
end-points, the incidence of adverse events, and changes in psychological status. A widely
used method to measure postoperative recovery is the Quality of Recovery 40 (QoR-40) survey.
The QoR-40 includes a total of 40 questions that may be divided into five sub-categories:
emotional state, physical comfort, psychological support, physical independence, and pain.
The respondent answers each question on a 5-point scale, with one being worst and five being
best. The QoR-40 takes 6.3 minutes on average to complete and is known to have good
test-retest reliability, internal consistency, and split-half reliability. With respect to
anesthetic recovery, the QoR-40 has been used in various studies to investigate how the
surgery type, anesthesia method, administration of an additional drug, and gender affect
anesthesia and surgery. The validity of the QoR-40 for research purposes has already been
established.
Therefore, in this study, we investigated the intraoperative intravenous injection of
lidocaine and the intravenous injection of magnesium to compare these drugs' helpfulness in
the functional recovery of thyroidectomy patients after general anesthesia.
Status | Completed |
Enrollment | 135 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients aged between 20 and 65 who have undergone thyroidectomy due to thyroid cancer and of American Society of Anesthesiologists (ASA) Physical Status Class 1 or Class 2 Exclusion Criteria: - Patients experiencing pain for any cause or taking an analgesic - Pregnant patients - Patients with severe heart, kidney, or liver disease - Patients with a psychiatric or neurological disorder - Patients with a contraindication or allergic response to lidocaine - Patients with a contraindication or allergic response to magnesium |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Anesthesiology and Pain MedicineSeverance Hospital, Yonsei University Health System | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint of this study was the QoR 40 | The quality of patient recovery after general anesthesia was evaluated by summing the scores for five subcategories—emotional state, physical comfort, psychological support, physical independence, and pain—to measure the global score (maximum of 200 points). The primary endpoint of this study was the QoR 40 at 24 hours after the operation. A difference between groups was considered significant when the difference in the score between two groups was 10 points or more. | 24 hours after the operation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |